Silver Book Fact

Donepezil, a new Alzheimer’s medication, increased prescription costs to $1,000 per patient, however the overall health care costs decreased from $11,947 to $8,056.

Hill J, Futterman R, Mastey V, Fillit H. The Effect of Donepezil Therapy on Health Costs in a Medicare Managed Care Plan. Managed Care Interface. 2002; 15(3): 63-70. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=11925682&dopt=AbstractPlus

Reference

Title
The Effect of Donepezil Therapy on Health Costs in a Medicare Managed Care Plan
Publication
Managed Care Interface
Publication Date
2002
Authors
Hill J, Futterman R, Mastey V, Fillit H
Volume & Issue
Volume 15, Issue 3
Pages
63-70
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Out-of-Pocket Costs, Slowed Progression  
  • According to the Pharmaceutical Research and Manufacturers of America, because of medical research, the number of Americans with Alzheimer’s could decrease by 3 million in 2025.  
  • A large set of NIH clinical trials are assessing interventions (including dietary supplements–creatine and coenzyme Q10) that may slow the progression of Parkinson’s disease.  
  • Deep brain stimulation, an electrical signal delivered deep inside the brain, provides significant symptomatic relief for Parkinson’s patients whose medication is no longer effective.  
  • A study of rasagiline mesylate in Parkinson’s disease patients showed improved motor fluctuations and other Parkinson’s disease symptoms.